PRESS RELEASE 2019
-
FerGene announces pivotal Phase 3 study of nadofaragene firadenovec met its primary endpoint with more than half of patients with high-grade non-muscle invasive bladder cancer (CIS ± Ta/T1) achieving a complete response at three months
The multi-center study met its primary endpoint with 53% of CIS ± Ta/T1 patients achieving a complete response (CR) at three months, and 24% continuing to show a CR at 12 months Additional data show 73% high-grade recurrence free (HGRF) survival in patients with papillary disease at three months ...
-
Ferring and Blackstone Life Sciences invest over $570 million USD in novel gene therapy for bladder cancer patients
Ferring launches new company FerGene, with a focus on the global development and US commercialization of nadofaragene firadenovec, for high-grade, Bacillus Calmette-Guérin unresponsive, non-muscle invasive bladder cancer patients Blackstone Life Sciences will invest $400 million USD and their exp...
-
Ferring Pharmaceuticals to Present New Fertility Data at ASRM 2019 Scientific Congress & Expo
• Ferring will deliver two oral presentations; one showcasing data from MEGASET-HR and the other discussing the influence of body weight on ovarian response in women undergoing stimulation as part of an in vitro fertilization (IVF) cycle • The company will also be sharing three poster presentatio...
-
Study Reveals: Nocturia Drains Nearly $215 Billion from the U.S. Economy
A comprehensive analysis of 22,300 non-patient individuals, of which 24.4% had nocturia (defined by the study as ≥2 urinations per night), demonstrated the association between nocturia and U.S. healthcare consumption and related costs.¹ Individuals with nocturia consumed significantly more health...
-
Response to FDA Safety Alert Regarding the Use of Fecal Microbiota for Transplantation
Parsippany, New Jersey – 14 June 2019 – Rebiotix and Ferring Pharmaceuticals were saddened to learn about the patients mentioned in the FDA’s safety alert regarding the use of Fecal Microbiota for transplantation and risk of serious adverse reactions due to transmission of multi-drug resistant or...
-
Ferring Pharmaceuticals appoints Sophie Opdyke to lead its new U.S. oncology division
Sophie Opdyke will be responsible for building Ferring’s new U.S. oncology division, leading its day-to-day operations, and shaping its long-term strategic business plan Opdyke’s role is Ferring’s first major executive appointment of 2019 in the U.S. Parsippany, N.J., USA, January 23, 2019 – Ferr...
-
Ferring Pharmaceuticals adds two products to its robust reproductive health portfolio in the U.S.
• Ferring acquired exclusive U.S. commercialization rights for generic Ganirelix Acetate Injection for the prevention of premature ovulation in women undergoing fertility treatment • Deal complete with INVO Bioscience Inc. for exclusive U.S. commercialization rights for the INVOcell™ Intravaginal...